Does TOFACITINIB Cause Neoplasm progression? 41 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 41 reports of Neoplasm progression have been filed in association with TOFACITINIB (XELJANZ XR). This represents 0.0% of all adverse event reports for TOFACITINIB.
41
Reports of Neoplasm progression with TOFACITINIB
0.0%
of all TOFACITINIB reports
13
Deaths
24
Hospitalizations
How Dangerous Is Neoplasm progression From TOFACITINIB?
Of the 41 reports, 13 (31.7%) resulted in death, 24 (58.5%) required hospitalization, and 19 (46.3%) were considered life-threatening.
Is Neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TOFACITINIB. However, 41 reports have been filed with the FAERS database.
What Other Side Effects Does TOFACITINIB Cause?
Drug ineffective (30,382)
Pain (21,659)
Condition aggravated (16,925)
Arthralgia (15,640)
Fatigue (13,551)
Rheumatoid arthritis (12,277)
Off label use (11,736)
Headache (11,061)
Joint swelling (10,686)
Malaise (9,040)
What Other Drugs Cause Neoplasm progression?
PALBOCICLIB (10,885)
SUNITINIB MALATE (1,920)
CYCLOPHOSPHAMIDE (1,588)
CARBOPLATIN (1,370)
AXITINIB (1,315)
DOXORUBICIN (1,276)
LETROZOLE (1,225)
PACLITAXEL (1,180)
CRIZOTINIB (1,161)
VINCRISTINE (1,106)
Which TOFACITINIB Alternatives Have Lower Neoplasm progression Risk?
TOFACITINIB vs TOFERSEN
TOFACITINIB vs TOLNAFTATE
TOFACITINIB vs TOLODODEKIN ALFA
TOFACITINIB vs TOLTERODINE
TOFACITINIB vs TOLVAPTAN